Current and emerging treatment approaches for splenic marginal zone lymphoma

References

• Neiman RS, Sullivan AL, Jaffe R. Malignant lymphoma simulating leukemic reticuloendotheliosis: a clinicopathologic study of ten cases. Cancer. 1979;43:329–342.
   PubMed Web of Science ®Google Scholar
• Melo JV, Robinson DS, Gregory C, et al. Splenic B cell lymphoma with “villous” lymphocytes in the peripheral blood: a disorder distinct from hairy cell leukemia. Leukemia. 1987;1:294–298.
   PubMed Web of Science ®Google Scholar
• Schmid C, Kirkham N, Diss T, et al. Splenic marginal zone cell lymphoma. Am J Surg Pathol. 1992;16:455–466.
   PubMed Web of Science ®Google Scholar
• Isaacson PG, Piris MA, Berger F, et al. Splenic B-cell marginal zone lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al., editors. World health organization classification of tumours: pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2008. p. 185–187.
   Google Scholar
• Liu L, Wang H, Chen Y, et al. Splenic marginal zone lymphoma: a population-based study on the 2001-2008 incidence and survival in the United States. Leuk Lymphoma. 2013;54:1380–1386.
   PubMed Web of Science ®Google Scholar
• Flowers CR, Sinha R, Vose JM. Improving outcomes for patients with diffuse large B-cell lymphoma. CA Cancer J Clin. 2010;60:393–408.
   PubMed Web of Science ®Google Scholar
• Matutes E, Oscier D, Montalban C, et al. Splenic marginal-zone lymphoma proposals for a revision of diagnosistic, staging and therapeutic criteria. Leukemia. 2008;22:487–395.
   PubMed Web of Science ®Google Scholar
• Catovsky D, Matutes E. Splenic lymphoma with circulating villous lymphocytes/splenic marginal-zone lymphoma. Semin Hematol. 1999;36:148–154.
   PubMed Web of Science ®Google Scholar
• Thieblemont C, Felman P, Callet-Bauchu E, et al. Splenic marginal-zone lymphoma: a distinct clinical and pathological entity. Lancet Oncol. 2003;4:95–103.
   PubMed Web of Science ®Google Scholar
• Iannitto E, Ambrosetti A, Ammatuna E, et al. Splenic marginal zone lymphoma with or without villous lymphocytes. Hematologic findings and outcomes in a series of 57 patients. Cancer. 2004;101:2050–2057.
   PubMed Web of Science ®Google Scholar
• Franco V, Florena AM, Campesi G. Intrasinusoidal bone marrow infiltration: a possible hallmark of splenic lymphoma. Histopathology. 1996;29:571–575.
   PubMed Web of Science ®Google Scholar
• Audouin J, Le Tourneau A, Molina T, et al. Patterns of bone marrow involvement in 58 patients presenting primary splenic marginal zone lymphoma with or without circulating villous lymphocytes. Br J Haematol. 2003;122:404–412.
   PubMed Web of Science ®Google Scholar
• Arcaini L, Paulli M, Boveri E, et al. Splenic and nodal marginal zone lymphomas are indolent disorders at high hepatitis C virus seroprevalence with distinct presenting features but similar morphologic and phenotypic profiles. Cancer. 2004;100:107–115.
   PubMed Web of Science ®Google Scholar
• Kanellis G, Mollejo M, Montes-Moreno S, et al. Splenic diffuse red pulp small B-cell lymphoma: revision of a series of cases reveals characteristic clinico-pathological features. Haematologica. 2010;95:1122–1129.
   PubMed Web of Science ®Google Scholar
• Zhu D, Orchard J, Oscier DG, et al. V(H) gene analysis of splenic marginal zone lymphomas reveals diversity in mutational status and initiation of somatic mutation in vivo. Blood. 2002;100:2659–2961.
   PubMed Web of Science ®Google Scholar
• Kalpadakis C, Pangalis GA, Dimitriadou E, et al. Mutation analysis of IgVH genes in splenic marginal zone lymphomas: correlation with clinical characteristics and outcome. Anticancer Res. 2009;5:1811–1816.
   Google Scholar
• Ruiz-Ballesteros E, Mollejo M, Rodriguez A, et al. Splenic marginal zone lymphoma: proposal of new diagnostic and prognostic markers identified after tissue and cDNA microarray analysis. Blood. 2005;106:1831–1838.
   PubMed Web of Science ®Google Scholar
• Bikos V, Darzentas N, Hadzidimitriou A, et al. Over 30% of patients with splenic marginal zone lymphoma express the same immunoglobulin heavy variable gene: ontogenetic implications. Leukemia. 2012;26:1638–1646.
   PubMed Web of Science ®Google Scholar
• Salido M, Baró C, Oscier D, et al. Cytogenetic aberrations and their prognostic value in a series of 330 splenic marginal zone B-cell lymphomas: a multicenter study of the splenic B-cell lymphoma group. Blood. 2010;116:1479–1488.
   PubMed Web of Science ®Google Scholar
• Rossi D, Trifonov V, Fangazio M, et al. The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development. JEM. 2012;209:1537–1551.
   PubMed Web of Science ®Google Scholar
• Kiel MJ, Velusamy T, Bryan L, et al. Whole-genome sequencing identifies recurrent somatic NOTCH2 mutations in splenic marginal zone lymphoma. JEM. 2012;209:1553–1565.
   PubMed Web of Science ®Google Scholar
• Piva R, Deaglio S, Famà R, et al. The Krüppel-like factor 2 transcription factor gene is recurrently mutated in splenic marginal zone lymphoma. Leukemia. 2015;29:503–507.
   PubMed Web of Science ®Google Scholar
• Clipson A, Wang M, De Leval L, et al. KLF2 mutation is the most frequent somatic change in splenic marginal zone lymphoma and identifies a subset with distinct genotype. Leukemia. 2015;29:1177–1185.
   PubMed Web of Science ®Google Scholar
• Parry M, Rose-Zerilli MJ, Ljungström V, et al. Genetics and prognostication in splenic marginal zone lymphoma: revelations from deep sequencing. Clin Cancer Res. 2015;21:4174–4183.
   PubMed Web of Science ®Google Scholar
• Camacho FI, Mollejo M, Mateo MS, et al. Progression to large B-cell lymphoma in splenic marginal zone lymphoma: a description of a series of 12 cases. Am J Surg Pathol. 2001;25:1268–1276.
   PubMed Web of Science ®Google Scholar
• Parry-Jones N, Matutes E, Gruszka-Westwood AM, et al. Prognostic features of splenic lymphoma with villous lymphocytes: a report on 129 patients. Br J Haematol. 2003;120:759–764.
   PubMed Web of Science ®Google Scholar
• Dungarwalla M, Appiah-Cubi S, Kulkarni S, et al. High-grade transformation in splenic marginal zone lymphoma with circulating villous lymphocytes: the site of transformation influences response to therapy and prognosis. Br J Haematol. 2008;143:71–74.
   PubMed Web of Science ®Google Scholar
• Arribas AJ, Rinaldi A, Mensah AA, et al. DNA methylation profiling identifies two splenic marginal zone lymphoma subgroups with different clinical and genetic features. Blood. 2015;125:1922–1931.
   PubMed Web of Science ®Google Scholar
• Conconi A, Franceschetti S, Aprile Von Hohenstaufen K, et al. Histologic transformation in marginal zone lymphomas. Ann Oncol. 2015;26:2329–2335.
   PubMed Web of Science ®Google Scholar
• Xing KH, Kahlon A, Skinnider BF, et al. Outcomes in splenic marginal zone lymphoma: analysis of 107 patients treated in British Columbia. Br J Haematol. 2015;169:520–527.
   PubMed Web of Science ®Google Scholar
• Meyer AH, Stroux A, Lerch K, et al. Transformation and additional malignancies are leading risk factors for an adverse course of disease in marginal zone lymphoma. Ann Oncol. 2014;25:210–215.
   PubMed Web of Science ®Google Scholar
• Arcaini L, Lazzarino M, Colombo N, et al. Splenic marginal zone lymphoma: a prognostic model for clinical use. Blood. 2006;107:4643–4649.
   PubMed Web of Science ®Google Scholar
• Montalban C, Abraira V, Arcaini L, et al. Simplification of the risk stratification for splenic marginal zone lymphoma: a point-based score for practical use. Leuk Lymphoma. 2014;55:929–931.
   PubMed Web of Science ®Google Scholar
• Montalban C, Arbraira V, Arcaini L, et al. Risk stratification for splenic marginal zone lymphoma based on haemoglobin concentration, platelet count, high lactate deydrogenase level and extrahilar lymphadenopathy: development and validation on 593 cases. Br J Haematol. 2012;159:164–171.
   PubMed Web of Science ®Google Scholar
• Kalpadakis C, Pangalis GA, Angelopoulou MK, et al. Validation of the simplified prognostic score for splenic marginal zone lymphoma of the splenic marginal zone lymphoma working group. Leuk Lymphoma. 2014;55:2640–2642.
   PubMed Web of Science ®Google Scholar
• Hermine O, Lefrère F, Bronowicki JP, et al. Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med. 2002;347:89–94.
   PubMed Web of Science ®Google Scholar
• Troussard X, Valensi F, Duchayne E, et al. Splenic lymphoma with villous lymphocytes: clinical presentation, biology and prognostic factors in a series of 100 patients. Br J Haematol. 1996;93:731–736.
   PubMed Web of Science ®Google Scholar
• Lenglet J, Traullé C, Mounier N, et al. Long-term follow-up analysis of 100 patients with splenic marginal zone lymphoma treated with splenectomy as first-line treatment. Leuk Lymphoma. 2014;55:1854–1860.
   PubMed Web of Science ®Google Scholar
• Franco V, Florena AM, Stella M, et al. Splenectomy influences bone marrow infiltration in patients with splenic marginal zone cell lymphoma with or without villous lymphocytes. Cancer. 2001;91:294–301.
   PubMed Web of Science ®Google Scholar
• Tsimberidou AM, Catovsky D, Schlette E, et al. Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone. Cancer. 2006;107:125–135.
   PubMed Web of Science ®Google Scholar
• Lefrère F, Hermine O, Belanger C, et al. Fludarabine: an effective treatment in patients with splenic lymphoma with villous lymphocytes. Leukemia. 2000;14:573–575.
   PubMed Web of Science ®Google Scholar
• Bolam S, Orchard J, Oscier D. Fludarabine is effective in the treatment of splenic lymphoma with villous lymphocytes. Br J Haematol. 1997;99:158–161.
   PubMed Web of Science ®Google Scholar
• Iannitto E, Minardi V, Calvaruso G, et al. Deoxycoformycin (pentostatin) in the treatment of splenic marginal zone lymphoma (SMZL) with or without villous lymphocytes. Eur J Haematol. 2005;75:130–135.
   PubMed Web of Science ®Google Scholar
• Lefrère F, Hermine O, François S, et al. Lack of efficacy of 2-chlorodeoxyadenoside in the treatment of splenic lymphoma with villous lymphocytes. Leuk Lymphoma. 2000;40:113–117.
   PubMed Web of Science ®Google Scholar
• Riccioni R, Caracciolo F, Galimberti S, et al. Low dose 2-CdA schedule activity in splenic marginal zone lymphomas. Hematol Oncol. 2003;21:163–168.
   PubMed Web of Science ®Google Scholar
• Bennett M, Sharma K, Yegena S, et al. Rituximab monotherapy for splenic marginal zone lymphoma. Haematologica. 2005;90:856–858.
   PubMed Web of Science ®Google Scholar
• Kalpadakis C, Pangalis GA, Dimopoulou MN, et al. Rituximab monotherapy is highly effective in splenic marginal zone lymphoma. Hematol Oncol. 2007;25:127–131.
   PubMed Web of Science ®Google Scholar
• Kalpadakis C, Pangalis GA, Vassilakopoulos TP, et al. Rituximab monotherapy is the treatment of choice for splenic marginal zone lymphoma (SMZL). Ann Oncol. 2008;19:Abstract #367.
   Web of Science ®Google Scholar
• Kalpadakis C, Pangalis GA, Angelopoulou MK, et al. Treatment of splenic marginal zone lymphoma with rituximab: progress report and comparison with splenectomy. Oncologist. 2013;18:190–197.
   PubMed Web of Science ®Google Scholar
• Kalpadakis C, Pangalis GA, Angelopoulou M, et al. Validation of the simplified prognostic score for SMZL of the SMZLSG (SMZL Study Group) in a series of patients treated with rituximab monotherapy, and long term outcome of rituximab responders. Haematologica. 2015;100(suppl 1):269.
   Google Scholar
• Else M, Marín-Niebla A, De La Cruz F, et al. Rituximab, used alone or in combination, is superior to other treatment modalities in splenic marginal zone lymphoma. Br J Haematol. 2012;159:322–328.
   PubMed Web of Science ®Google Scholar
• Fabbri A, Gozzetti A, Lazzi S, et al. Activity of rituximab monotherapy in refractory splenic marginal zone lymphoma complicated with autoimmune hemolytic anemia. Clin Lymphoma Myeloma. 2006;6:496–499.
   PubMedGoogle Scholar
• Paydas S, Yavuz S, Disel U, et al. Successful rituximab therapy for hemolytic anemia associated with relapsed splenic marginal zone lymphoma with leukemic phase. Leuk Lymphoma. 2003;44:2165–2166.
   PubMed Web of Science ®Google Scholar
• Kalpadakis C, Pangalis GA, Sachanas S, et al. No evidence of splenic disease in patients with splenic marginal zone lymphoma after rituximab monotherapy who underwent splenectomy due to autoimmune haemolytic anaemia. Report of two cases. Leuk Lymphoma. 2016;15:1–4.
   Web of Science ®Google Scholar
• Arcaini L, Orlandi E, Scotti M, et al. Combination of rituximab, cyclophosphamide, and vincristine induces complete hematologic remission of splenic marginal zone lymphoma. Clin Lymphoma. 2004;4:250–252.
   PubMedGoogle Scholar
• Brown JR, Friedberg JW, Feng Y, et al. A phase 2 study of concurrent fludarabine and rituximab for the treatment of marginal zone lymphomas. Br J Haematol. 2009;145:741–748.
   PubMed Web of Science ®Google Scholar
• Cervetti G, Galimberti S, Sordi E, et al. Significant efficacy of 2-chlorodeoxyadenosine {±} rituximab in the treatment of splenic marginal zone lymphoma (SMZL). Ann Oncol. 2010;21:851–854.
   PubMed Web of Science ®Google Scholar
• Cervetti G, Galimberti S, Pelosini M, et al. Significant efficacy of 2-chlorodeoxyadenosine {+/-} rituximab in the treatment of splenic marginal zone lymphoma (SMZL): extended follow-up. Ann Oncol. 2013;24:2434–2438.
   PubMed Web of Science ®Google Scholar
• Iannitto E, Luminari S, Tripodo C, et al. Rituximab with cyclophosphamide, vincristine, non-pegylated liposomal doxorubicin and prednisone as first-line treatment for splenic marginal zone lymphoma: a Fondazione Italiana Linfomi phase II study. Leuk Lymphoma. 2015;56:3281–3287.
   PubMed Web of Science ®Google Scholar
• Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013;381:1203–1210.
   PubMed Web of Science ®Google Scholar
• Fowler NH, Davis RE, Rawal S, et al. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial. Lancet Oncol. 2014;15:1311–1318.
   PubMed Web of Science ®Google Scholar
• Tuscano JM, Dutia M, Chee K, et al. Lenalidomide plus rituximab can produce durable clinical responses in patients with relapsed or refractory, indolent non-Hodgkin lymphoma. Br J Haematol. 2014;165:375–381.
   PubMed Web of Science ®Google Scholar
• Sacchi S, Marcheselli R, Bari A, et al. Safety and efficacy of lenalidomide in combination with rituximab in recurrent indolent non-follicular lymphoma: final results of a phase II study conducted by the Fondazione Italiana Linfomi. Haematologica. 2016 ;101(5):e196-9.
   PubMed Web of Science ®Google Scholar
• Sehn LH, Chua NS, Mayer J, et al. GADOLIN: primary results from a phase III study of obinutuzumab plus bendamustine compared with bendamustine alone in patients with rituximab-refractory indolent non-Hodgkin lymphoma. J Clin Oncol. 2015;33(suppl):abstr LBA8502. ASCO meeting 2015.
   Google Scholar
• Gopal AK, Kahl BS, De Vos S, et al. PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med. 2014;370:1008–1018.
   PubMed Web of Science ®Google Scholar
• Advani RH, Buggy JJ, Sharman JP, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol. 2013;31:88–94.
   PubMed Web of Science ®Google Scholar
• Chen R, Frankel P, Popplewell L, et al. A phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed/refractory indolent non-Hodgkin lymphoma. Haematologica. 2015;100(3):357–362.
   PubMed Web of Science ®Google Scholar
• Cohen JB, Switchenko JM, Koff JL, et al. A phase II study of bortezomib added to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with previously untreated indolent non-Hodgkin’s lymphoma. Br J Haematol. 2015;171:539–546.
   PubMed Web of Science ®Google Scholar
• Witzig TE, Wiernik PH, Moore T, et al. Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin’s Lymphoma. J Clin Oncol. 2009;27:5404–5409.
   PubMed Web of Science ®Google Scholar
• Ahmadi T, Chong EA, Gordon A, et al. Combined lenalidomide, low-dose dexamethasone, and rituximab achieve durable responses in rituximab-resistant indolent and mantle cell lymphomas. Cancer. 2014;120:222–228.
   PubMed Web of Science ®Google Scholar
• Chong EA, Ahmadi T, Aqui NA, et al. Combination of lenalidomide and rituximab overcomes rituximab resistance in patients with indolent B-cell and mantle cell lymphomas. Clin Cancer Res. 2015;21:1835–1842.
   PubMed Web of Science ®Google Scholar
• Goede V, Fischer K, Busch R, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med. 2014 Mar 20;370:1101–1110.
   PubMed Web of Science ®Google Scholar
• Goede V, Fischer K, Engelke A, et al. Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study. Leukemia. 2015;29:1602–1604.
   PubMed Web of Science ®Google Scholar
• Salles GA, Morschhauser F, Solal-Céligny P, et al. Obinutuzumab (GA101) in patients with relapsed/refractory indolent non-Hodgkin lymphoma: results from the phase II GAUGUIN study. J Clin Oncol. 2013;31:2920–2926.
   PubMed Web of Science ®Google Scholar
• Lannutti BJ, Meadows SA, Herman SE, et al. CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood. 2011;117:591–594.
   PubMed Web of Science ®Google Scholar
• Benson DM, Kahl BS, Furman RR, et al. Final results of a phase I study of idelalisib, a selective inhibitor of PI3Kδ, in patients with relapsed or refractory indolent non-Hodgkin lymphoma (iNHL). J Clin Oncol. 2013;31(Suppl):8526.abstract.
   Google Scholar
• Brown JR, Furman RR, Flinn I, et al. Final results of a phase I study of idelalisib (GSE-1101) a selective inhibitor of PI3Kδ, in patients with relapsed or refractory CLL. J Clin Oncol. 2013;31(Suppl):7003.abstract.
   Google Scholar
• Gopal AK, Kahl BS, De Vos S, et al. Mature follow-up from a phase 2 study of PI3K-delta inhibitor idelalisib in patients with double (rituximab and alkylating agent)-refractory indolent B-cell non-Hodgkin lymphoma. Blood. 2014;124:1708 (abstract).
   Web of Science ®Google Scholar
• Cheah CY, Nastoupil LJ, Neelapu SS, et al. Lenalidomide, idelalisib, and rituximab are unacceptably toxic in patients with relapsed/refractory indolent lymphoma. Blood. 2015;125:3357–3359.
   PubMed Web of Science ®Google Scholar
• Maddocks K, Christian B, Jaglowski S, et al. A phase 1/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed/refractory non-Hodgkin lymphoma. Blood. 2015;125:242–248.
   PubMed Web of Science ®Google Scholar
• Kirschbaum M, Frankel P, Popplewell L, et al. Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin’s lymphoma and mantle cell lymphoma. J Clin Oncol. 2011;29:1198–1203.
   PubMed Web of Science ®Google Scholar
• Troch M, Jonak C, Müllauer L, et al. A phase II study of bortezomib in patients with MALT lymphoma. Haematologica. 2009;94:738–742.
   PubMed Web of Science ®Google Scholar
• Di Bella N, Taetle R, Kolibaba K, et al. Results of a phase 2 study of bortezomib in patients with relapsed or refractory indolent lymphoma. Blood. 2010;115:475–480.
   PubMed Web of Science ®Google Scholar
• Conconi A, Martinelli G, Lopez-Guillermo A, et al.; International Extranodal Lymphoma Study Group (IELSG). Clinical activity of bortezomib in relapsed/refractory MALT lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group (IELSG). Ann Oncol. 2011;22:689–695.
   PubMed Web of Science ®Google Scholar
• Baiocchi RA, Alinari L, Lustberg ME, et al. Phase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphoma. Cancer. 2011;117:2442–2451.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Osmanov EA, Hong X, et al. LYM-3001 study investigators. Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial. Lancet Oncol. 2011;12:773–784.
   PubMed Web of Science ®Google Scholar
• Fowler N, Kahl BS, Lee P, et al. Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: the phase II VERTICAL study. J Clin Oncol. 2011;29:3389–3395.
   PubMed Web of Science ®Google Scholar
• Sehn LH, MacDonald D, Rubin S, et al. Bortezomib ADDED to R-CVP is safe and effective for previously untreated advanced-stage follicular lymphoma: a phase II study by the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2011;29:3396–3401.
   PubMed Web of Science ®Google Scholar
• Nabhan C, Villines D, Dalal N, et al. Bortezomib (Velcade), rituximab, cyclophosphamide, and dexamethasone combination regimen is active as front-line therapy of low-grade non-Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk. 2012;12:26–31.
   PubMed Web of Science ®Google Scholar
• Conconi A, Raderer M, Franceschetti S, et al. Clinical activity of everolimus in relapsed/refractory marginal zone B-cell lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group. Br J Haematol. 2014;166:69–76.
   PubMed Web of Science ®Google Scholar
• Fowler N, Pinto RM, Cheah CY, et al. A phase I study of lenalidomide plus a next generation anti-CD20 antibody, obinutuzumab, in relapsed indolent lymphoma. Blood. 2015;126:2742 (abstract).
   Web of Science ®Google Scholar
• Christian BA, Kuruvilla JG, Smith SM, et al. Updated results of a phase I study of ibrutinib and lenalidomide in patients with relapsed and refractory B-cell non-Hodgkin’s lymphoma. Blood. 2015;126:3983 (abstract).
   Google Scholar
• Kalpadakis C, Pangalis GA, Vassilakopoulos TP, et al. Treatment of splenic marginal zone lymphoma: should splenectomy be abandoned? Leuk Lymphoma. 2014;55:1463–1470.
   PubMed Web of Science ®Google Scholar
• Bennett M, Schechter GP. Treatment of splenic marginal zone lymphoma: splenectomy versus rituximab. Semin Hematol. 2010;47:143–147.
   PubMed Web of Science ®Google Scholar